UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

Abiraterone and Increased Survival in Metastatic Prostate Cancer

The New England journal of medicine, 2011-05, Vol.364 (21), p.1995-2005

2011

Volltextzugriff (PDF)

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer

Cells (Basel, Switzerland), 2020-10, Vol.9 (11), p.2342

2020

Volltextzugriff (PDF)

SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus

BMC cancer, 2011-10, Vol.11 (1), p.466-466, Article 466

2011

Volltextzugriff (PDF)

Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer

Cells (Basel, Switzerland), 2024-04, Vol.13 (8), p.673

2024

Volltextzugriff (PDF)

Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting

BJU international, 2021-03, Vol.127 (3), p.304-306

2021

Volltextzugriff (PDF)

Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)

European urology oncology, 2021-12, Vol.4 (6), p.980-992

2021

Volltextzugriff (PDF)

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

European urology oncology, 2018-12, Vol.1 (6), p.449-458

2018

Volltextzugriff (PDF)

Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement

Radiotherapy and oncology, 2004, Vol.70 (1), p.1-10

2004

Volltextzugriff (PDF)

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

The New England journal of medicine, 2023-02, Vol.388 (8), p.719-732

2023

Volltextzugriff (PDF)

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

The New England journal of medicine, 2023-04, Vol.388 (17), p.1547-1558

2023

Volltextzugriff (PDF)

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial

The lancet oncology, 2013-06, Vol.14 (7), p.627-637

2013

Volltextzugriff (PDF)

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial

The lancet oncology, 2013-04, Vol.14 (4), p.317-326

2013

Volltextzugriff (PDF)

Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (4), p.810-818

2015

Volltextzugriff (PDF)

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

The lancet oncology, 2019-11, Vol.20 (11), p.1531-1543

2019

Volltextzugriff (PDF)

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

The lancet oncology, 2022-10, Vol.23 (10), p.1308-1320

2022

Volltextzugriff (PDF)

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy

European journal of cancer (1990), 2013-11, Vol.49 (17), p.3648-3657

2013

Volltextzugriff (PDF)

External validation of a prognostic model incorporating quantitative PET image features in oesophageal cancer

Radiotherapy and oncology, 2019-04, Vol.133, p.205-212

2019

Volltextzugriff (PDF)

A comparison of CT- and ultrasound-based imaging to localize the prostate for external beam radiotherapy

International journal of radiation oncology, biology, physics, 2006-07, Vol.65 (3), p.678-687

2006

Volltextzugriff (PDF)

Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2012-02, Vol.30 (5_suppl), p.15-15

2012

Volltextzugriff (PDF)

Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4558-4558

2012

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Male
(19)
Oncology
(17)
Prostate Cancer
(11)
Patients
(9)
Treatment Outcome
(9)
Aged
(8)
Chemotherapy
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Cancer Therapies
(7)
Middle Aged
(7)
Prostatic Neoplasms - Pathology
(6)
Hematology, Oncology And Palliative Medicine
(5)
Medical Research
(5)
Prostatic Neoplasms - Radiotherapy
(5)
Quality Of Life
(5)
Adult
(4)
Androgens
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Abiraterone and Increased Survival in Metastatic Prostate Cancer

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer

SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus

Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer

Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting

Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial

Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Clinical development of new drug-radiotherapy combinations

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy

External validation of a prognostic model incorporating quantitative PET image features in oesophageal cancer

A comparison of CT- and ultrasound-based imaging to localize the prostate for external beam radiotherapy

Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment

Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC)

Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC)

Suchergebnisse filtern